Climb Bio | 4: Statement of changes in beneficial ownership of securities-Officer Pimblett Emily
Climb Bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(3.23%),Deep Track Biotechnology Master Fund, Ltd.(3.23%), etc.
Climb Bio | 4: Statement of changes in beneficial ownership of securities-Director WILLIAMS DOUGLAS E
Climb Bio | 3: Initial statement of beneficial ownership of securities-Director WILLIAMS DOUGLAS E
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pimblett Emily
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kaplan Brett
Eliem Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Kaplan Brett
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Eliem Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Affinity Healthcare Fund, LP (EIN(2.70%),Affinity Asset Advisors, LLC (EIN(2.70%)
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | D: Filing D
Eliem Therapeutics | D: Filing D
Eliem Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(5.85%),Deep Track Biotechnology Master Fund, Ltd.(5.85%), etc.
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
No Data